39 Lower-dose oral semaglutide 25 mg has also shown substantial benefit, with an estimated mean weight reduction of 13.6% at 64 weeks
The rising interest in GLP1 MASLD MASH treatment has transformed how clinicians view metabolic therapies for patients with type 2 diabetes and obesity
Research suggests GLP-1 medications may treat kidney disease, neurodegenerative disorders, and gastrointestinal conditions, among other non-approved conditions
Dual GLP-1/GIP receptor agonists, such as tirzepatide, simultaneously activate both receptors, thereby potentiating glycemic control, promoting weight loss, and ameliorating metabolic dysfunction
Consistency is key when taking retatrutide
"With a reduction of calories, its so important that enough protein is eaten throughout the day at all three meals